Treatment Resistant Depression Market Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030
Treatment Resistant Depression
Depression is a mental condition
characterised by persistent sadness and loss of interest. It has an impact on
how patients feel, think, and behave, and it can lead to a variety of mental
and physical problems. It is also referred to as major depression or clinical
depression. Patients may find it difficult to perform daily tasks. Depression
is a common and serious medical condition that has a negative impact on how
people feel, think, and act. Patients suffering from depression experience
melancholy and/or a loss of interest in previously enjoyed activities. It can
result in a wide range of emotional and physical problems.
Key market players are involved
in obtaining approvals for and launching novel treatment resistant depression
drugs. Such approval and launch of novel drugs indicated for treatment resistant
depression is expected to drive Treatment
Resistant Depression market growth
over the forecast period. For example, Denovo Biopharma LLC, a clinical-stage
biopharmaceutical company focused on the development of biomarker-driven
precision medicines, announced in January 2022 that the U.S. Food and Drug
Administration (FDA) has authorised the company's investigational new drug
(IND) application of DB104 (liafensine) for treatment-resistant depression
(TRD) to proceed, allowing Denovo to begin a global Phase 2b clinical trial to
assess the safety and efficacy.
Over the forecast period, the
increasing prevalence of depression is expected to drive growth in the global
treatment resistant depression market. For example, according to
National Institute of Mental Health data published in January 2022, an
estimated 21.0 million adults in the United States experienced at least one
major depressive episode in 2020. In 2020, this figure represented 8.4% of all
adults in the United States.
Comments
Post a Comment